MilliporeSigma* recently commissioned Economist Intelligence Clearstate, a division of The Economist, to conduct a study on the future of vaccine manufacturing in the Asia Pacific region. Nearly forty industry executives from biopharmaceutical companies, contract development and manufacturing organizations, and research institutes across ten countries were interviewed on topics ranging from the pros and cons of different vaccine modalities to technology adoption and envisioning the facility of the future.
In this whitepaper, we share key findings from this research on the future of vaccine manufacturing in the Asia Pacific region. Our perspective on the survey findings are offered by Josephine Cheng, one of our senior Process Solutions consultants based in Taiwan.
* MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.